Chemotherapy re-use versus anti-angiogenic monotherapy as the third-line treatment of patients with metastatic colorectal cancer: a real-world cohort study
Abstract Background There are various recommendations for third-line treatment in mCRC, however, there is no consensus on who is more suitable for particular strategy. Chemotherapy re-use in third-line setting is a common option in clinical practice. This study aimed to investigate the efficacy of t...
Main Authors: | Jingjing Duan, Lila Zhu, Yinghui Shi, Weixue Wang, Tongtong Wang, Tao Ning, Le Zhang, Ming Bai, Hongli Li, Rui Liu, Shaohua Ge, Xia Wang, Yuchong Yang, Zhi Ji, Feixue Wang, Yansha Sun, Yi Ba, Ting Deng |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2024-03-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12885-024-12072-5 |
Similar Items
-
Sintilimab Plus Apatinib and Chemotherapy as Second‑/Third-Line treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a prospective, Single-Arm, phase II trial
by: Le Zhang, et al.
Published: (2023-03-01) -
Third-line treatment patterns and clinical outcomes for metastatic colorectal cancer: a retrospective real-world study
by: Ting Deng, et al.
Published: (2023-09-01) -
Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer
by: Elif Şenocak Taşçı, et al.
Published: (2024-01-01) -
The Concept of ‘Third Generation Rights’
by: Mohammad Rasekh, et al.
Published: (2013-11-01) -
The University’s third mission and third-places
by: Etienne Bou Abdo, et al.